Skip to main content
OpenTrials
Completed

NCT Number: NCT02090361

Efficacy of Collagen-elastin Dermal Substitute in the Treatment of Loss of Cutaneous Substances With Skin Grafts

In reconstructive surgery , most losses of cutaneous substance require the use of a thin skin graft . This technique allows epidermization of the defect by applying a thin layer of autologous epidermis. It does not reconstitute the injured skin. Transplants cause retractile scars, adherent to the deep plan, that may require revision surgery . Since a decade , dermal matrices are mainly used in burned skin centers . The collagen -elastin matrix has the advantage to set up in the same operation that the skin graft and contain elastic fibers , two assets which improve the results of skin grafting.

Objective:

Evaluation of the clinical efficacy of the addition of a dermal matrix to skin graft on Skin Foldability, at day 360.

Methodology:

This is a multicenter randomized study (CHU Caen , Amiens, Rouen and Lille)

Conduct of the study :

The transplant will be performed according to the protocol defined between inter -region surgeons. The implementation of the dermal matrix will be in the same surgical technique as thin skin graft ( group 1 ) or the thin skin graft will be performed alone ( group 2) time .

Evaluation Criteria Main : Skin Foldability ( Uf ) assessed grafted site will be compared to the opposite side ungrafted evaluated at Day 360 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH).

To achieve the main objective, it is planned to compare the ratio between Uf graft site and the opposite healthy site between two groups: skin + matrix graft , or skin graft only. Thus, the Wilcoxon test for independent samples will be used to settle bilateral formulation between the null hypothesis ( there is no difference between the two groups ) and the alternative hypothesis ( there is a difference between the two groups ) . In determining the overall risk of first species to 5% and the power of this test to detect the 90% expected under the alternative hypothesis difference should be the main criterion for evaluating at least 59 patients in each group so 118 patients total.

Prospect If the contribution of a dermal matrix in loss of skin substances improves skin pliability and reduces pain , functional and aesthetic sequelae grafts thin skin , the dermal matrix may be proposed as a complementary treatment in these indications.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU d'Amiens, Amiens, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged over 18
  • Signed informed consent
  • Patients with loss of cutaneous substance of at least 15 cm2
  • Patient Without bone exposure, vascular, joint or tendon
  • Eligibility for surgical treatment by skin graft
  • Loss of substance trauma (avulsion, burns) or surgery (skin excision)

Exclusion criteria

  • Patient with a chronic wound
  • Wound superinfected
  • Patient unable for local or general skin graft
  • Patient with an old or a recent skin injury strictly contralateral to the graft site.
  • Patient unable to consent

Treatment and study plan

Skin Graft

Procedure

Epidermization of the defect by applying a thin layer of autologous epidermis

Primary outcomes

  1. Skin Foldability ( Uf )

    Time frame: Day 360

    Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D360 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH).

Secondary outcomes

  1. Skin Foldability ( Uf )

    Time frame: Day 180

    Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D180 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH)

  2. Skin Foldability ( Uf )

    Time frame: Day 90

    Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D90 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH)

  3. Pain on the grafted site

    Time frame: D7

    Assessment of pain on the grafted site EVA at Day 7

  4. pain on the grafted site

    Time frame: Day 15

    Assessment of pain on the grafted site at Day 15

  5. pain on the grafted site

    Time frame: Day 30

    Assessment of pain at the grafted site EVA to D30

  6. pain on the grafted site

    Time frame: Day 90

    Assessment of pain at the grafted site EVA at D30

  7. pain on the grafted site

    Time frame: Day 180

    Assessment of pain at the grafted site EVA at Day 180

  8. pain on the grafted site

    Time frame: Day 360

    Assessment of pain at the grafted site EVA at Day 360

  9. tolerance of matriderm use

    Time frame: Day 360

    Occurrence within 360 days of a local complication requiring reoperation

  10. Area healed

    Time frame: Day 7

    Evaluation of the percentage of area healed at Day 7

  11. Area healed

    Time frame: Day 15

    Evaluation of the percentage of area healed at Day 15

  12. Area healed

    Time frame: Day 30

    Evaluation of the percentage of area healed at Day 30

  13. Assessment of functional effects

    Time frame: Day 30

    Assessment of functional effects of the scar on the patient 's daily activities defined at Day 30

  14. Assessment of functional effects

    Time frame: Day 90

    Assessment of functional effects of the scar on the patient 's daily activities defined at Day 90

  15. Assessment of functional effects

    Time frame: Day 180

    Assessment of functional effects of the scar on the patient 's daily activities defined at Day 180

  16. Assessment of functional effects

    Time frame: Day 360

    Assessment of functional effects of the scar on the patient 's daily activities defined at Day 360

  17. Aesthetic sequelae evaluation

    Time frame: Day 90

    Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 90

  18. Aesthetic sequelae evaluation

    Time frame: Day 180

    Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 180

  19. Aesthetic sequelae evaluation

    Time frame: Day 360

    Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 360

Sponsors and collaborators

Lead sponsor

University Hospital, Rouen

Other

Registry information

Acronym: MATRIGREFFE

Important dates

Study start
2014
Primary completion
2019
Study completion
2019
First posted
Mar 18, 2014
Registry last updated
Feb 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.